Search Results 441-450 of 17432 for prednisone

  1. Phase 1/2 Dose Escalation Study in Patients With Relapsed or Refractory Waldenstrom's Macroglobulinemia - Mayo Clinic

    Receiving chronic systemic corticosteroid therapy > 20 mg of prednisone daily. Being treated with other anti-cancer therapies (approved or investigational) ...

  2. Sulindac (oral route) - Mayo Clinic

    Sulindac is a nonsteroidal anti-inflammatory drug (NSAID) used to treat mild to moderate pain and help relieve symptoms of arthritis (e.g., osteoarthritis and ...

  3. Nivolumab in Treating Patients With Recurrent and/or Metastatic Nasopharyngeal Cancer - Mayo Clinic

    ... prednisone or equivalents) for at least 2 weeks prior to study drug administration; patients with treated brain metastases who are deemed clinically stable ...

  4. Testing the Addition of an Anti-cancer Drug, ASTX727, to Chemotherapy (Paclitaxel) and Immunotherapy (Pembrolizumab) for Metastatic Triple-Negative Breast Cancer - Mayo Clinic

    - Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form ...

  5. Chloramphenicol (ophthalmic route) - Mayo Clinic

    Chloramphenicol ophthalmic preparations are used to treat infections of the eye. This medicine may be given alone or with other medicines that are taken by ...

  6. A Study to Evaluate UV1 Vaccination Plus Nivolumab and Ipilimumab in Treatment of Melanoma - Mayo Clinic

    ... prednisone equivalents. Receipt of a live vaccine within 30 days prior to the start of induction therapy performed to determine eligibility. Women who are ...

  7. ARrest RESpiraTory Failure From PNEUMONIA - Mayo Clinic

    A condition requiring inhaled corticosteroids or beta-agonists, or chronic systemic steroid therapy equivalent to a dose >10 mg prednisone (this does not ...

  8. A Study to Evaluate the Effectiveness and Safety of Benralizumab in Patients with Hypereosinophilic Syndrome (HES) - Mayo Clinic

    ... (prednisone/prednisolone) 1 mg/kg/day at Visit 2 (assessed by local laboratory). Other OCSs in equivalent doses are permitted 9. WOCBP must agree to use a ...

  9. XmAb®20717 Alone or in Combination With Chemotherapy or Targeted Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer - Mayo Clinic

    Subjects who are currently taking prednisone from a previous prostate cancer therapy will be permitted to enroll in the study. * Receipt of an organ allograft * ...

  10. Immunosuppressive Drugs Clinical Trials - Mayo Clinic Research

    The study is a Phase II randomized, open label, multicenter trial designed to identify whether sirolimus is a potential alternative to prednisone as an up ...